Watch the latest episode of focusIR Fireside Chats: Why Edinburgh Investment Trust Is Backing Turnaround Stocks for 2026 Growth. View here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksGenus Regulatory News (GNS)

Share Price Information for Genus (GNS)

Share Price is delayed by 15 minutes
Get Live Data
2,158.00    26.00 (1.22%)
Bid:
2,156.00
Ask:
2,166.00
Spread: 10.00 (0.464%)
Market Cap: £1.43b
GNS Live PriceLast checked at - London Stock Exchange

Intraday Genus Share Chart

Senior Management Changes

4 Jan 2012 07:00

RNS Number : 9387U
Genus PLC
04 January 2012
Β 

ο»Ώ

Β 

For immediate release 4 January 2012

Β 

Β 

Β 

Β 

Β 

Β 

Β 

GENUS plc

("Genus" or "the Company")

Β 

Senior Management Changes

Β 

Genus, a leading global animal genetics company, announces two senior management changes within the Group.

Β 

Firstly, Genus is delighted to announce that Catherine Glickman will join the Company as Group Human Resources (HR) Director on January 5th 2012. Catherine will be leading the Group's talent management strategy as well as taking responsibility for engaging, equipping and investing in Genus employees to help the Group deliver its ambitious plans for growth. Catherine will become a member of the Genus Executive Leadership Team and will report directly to Karim Bitar, Chief Executive Officer.

Β 

Until recently, Catherine was the Head of HR at Tesco, one of the five largest global retailers with over 500,000 employees in 14 countries. During her 20 years at Tesco she was instrumental in developing the HR strategy that helped drive the retailer's strong growth and international expansion in recent years. Overall, she has over 25 years' experience in HR, within Tesco and beyond.

Β 

Secondly, Denny Funk Ph.D, the Company's Chief Scientific Officer, has also joined the Genus Executive Leadership Team. Dr. Funk will report directly to Karim Bitar, Chief Executive, and will have full responsibility for the Company's research & development (R&D) programme. This will ensure that R&D has a key and highly visible role as Genus pursues its ambitious plans for the future. Dr. Denny Funk was an Associate Professor at the University of Wisconsin-Madison before joining Genus in 1995.

Β 

Separately, Ian Biggs, formerly Head of Global Product and Business Strategy, has stepped down from his role to pursue other opportunities outside Genus. His primary responsibilities will be assumed by Dr. Denny Funk.

Β 

Karim Bitar, Chief Executive, commented:

Β 

Β "I am delighted to announce the appointment of such a high calibre and experienced individual as Catherine to the role of Group HR Director. Catherine has been attracted and inspired by the Group's ambitious plans and is as enthusiastic as I am about the opportunities ahead. She will play a major role as she helps shape our talent management strategy."

Β 

"I would like thank Ian for the contribution he has made to Genus over the years and we wish him all the best for the future. Lastly, I am delighted that Denny has taken overall responsibility for R&D and I look forward to working with him closely as we ensure R&D plays a clear and consistent part in helping Genus meet evolving customer and market needs."

Β 

Β 

Β 

Β 

Β 

For further information please contact:

Β 

Genus plc Tel: 01256 345970

Karim Bitar, Chief Executive

John Worby, Finance Director

Β 

Buchanan Tel: 0207 466 5000

Charles Ryland, Suzanne Brocks, Catherine Breen

www.buchanan.uk.comΒ 

Β 

Β 

This announcement is available on the Genus website, www.genusplc.com

Β 

Β 

About Genus

Β 

Genus creates advances to animal breeding through biotechnology and sells added value products for livestock farming and food producers. Its non-genetically modified organism technology is applicable across all livestock species but is only commercialised by Genus in the bovine and porcine farming sectors.

Β 

Genus' worldwide sales are made in seventy countries under the trademarks "ABS" (dairy and beef cattle) and "PIC" (pigs) and comprise semen and breeding animals with superior genetics to those animals currently in production. Customers' animals produce offspring with greater production efficiency, milk and meat output and quality, and use these to supply the global dairy and meat supply chain.

Β 

The Group's competitive edge has been created from the ownership and control of proprietary lines of breeding animals, the biotechnology used to improve them and its global production and distribution network.

Β 

With headquarters in Basingstoke, England, Genus companies operate in thirty countries on six continents, with research laboratories located in Madison, Wisconsin, USA

Β 

Β 

This information is provided by RNS
The company news service from the London Stock Exchange
Β 
END
Β 
Β 
MSCBJMRTMBJMBLT
Date   Source Headline
31st Jul 20122:00 pmRNSTotal Voting Rights
31st Jul 20127:00 amRNSJoint Venture in China
4th Jul 20127:00 amRNSPre-Close Trading Statement
15th May 20124:09 pmRNSHolding(s) in Company
15th May 20124:08 pmRNSHolding(s) in Company
3rd May 20127:00 amRNSInterim Management Statement and Strategy Update
30th Apr 20122:00 pmRNSTotal Voting Rights
30th Mar 20122:00 pmRNSTotal Voting Rights
14th Mar 20122:00 pmRNSDirector/PDMR Shareholding
29th Feb 20122:00 pmRNSTotal Voting Rights
27th Feb 20124:25 pmRNSHolding(s) in Company
21st Feb 20123:16 pmRNSHolding(s) in Company
21st Feb 20122:30 pmRNSDirector/PDMR Shareholding
21st Feb 20127:00 amRNSInterim Results
31st Jan 20122:00 pmRNSBlocklisting Interim Review
31st Jan 201210:44 amRNSNotice of Results
16th Jan 20123:49 pmRNSHolding(s) in Company
4th Jan 20127:00 amRNSSenior Management Changes
30th Dec 201112:00 pmRNSTotal Voting Rights
30th Nov 20112:00 pmRNSTotal Voting Rights
10th Nov 201112:51 pmRNSResult of AGM
10th Nov 20117:00 amRNSAGM and Interim Management Statement
31st Oct 20112:00 pmRNSTotal Voting Rights
27th Oct 20112:00 pmRNSAnnual Information Update
11th Oct 201111:39 amRNSAnnual Report and Annual General Meeting
30th Sep 20112:44 pmRNSTotal Voting Rights
22nd Sep 20112:33 pmRNSHolding(s) in Company
20th Sep 20113:08 pmRNSAdditional Listing
20th Sep 20113:07 pmRNSDirector/PDMR Shareholding
9th Sep 201111:00 amRNSDirector/PDMR Shareholding
6th Sep 20117:00 amRNSPreliminary Results
31st Aug 20112:00 pmRNSTotal Voting Rights
29th Jul 20112:00 pmRNSBlocklisting Interim Review
29th Jul 20112:00 pmRNSTotal Voting Rights
4th Jul 20117:00 amRNSPre-close Trading Statement
25th May 20117:00 amRNSCEO Retirement and Appointment of Successor
12th May 20112:08 pmRNSHolding(s) in Company
11th May 20117:00 amRNSInterim Management Statement
28th Apr 20112:00 pmRNSTotal Voting Rights
31st Mar 20112:00 pmRNSTotal Voting Rights
10th Mar 20115:56 pmRNSHolding(s) in Company
9th Mar 201111:00 amRNSDirector Shareholding
28th Feb 20112:37 pmRNSTotal Voting Rights
22nd Feb 20117:00 amRNSInterim Results
31st Jan 20112:00 pmRNSBlocklisting Interim Review
31st Jan 20112:00 pmRNSTotal Voting Rights
27th Jan 20113:57 pmRNSNotice of Results
21st Jan 20113:36 pmRNSHolding(s) in Company
30th Nov 20102:00 pmRNSTotal Voting Rights
26th Nov 20104:27 pmRNSHolding(s) in Company

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.